As the Ebola outbreak in the Democratic Republic of Congo (DRC) continues to raise global concern, the United States has taken a significant step by releasing doses of an experimental antibody treatment to support clinical trials in the affected region. The move is expected to strengthen efforts to combat one of the deadliest viral diseases while accelerating research into potentially life-saving therapies.
The decision marks a notable shift in U.S. policy. Previously, access to the treatment was largely restricted to domestic use, with only limited international availability. Health experts believe the expanded access could provide valuable scientific data and offer hope to communities battling the rapidly spreading outbreak.
According to officials from the U.S. Department of Health and Human Services, the experimental drug developed by Mapp Biopharmaceutical will be provided for compassionate use in Congo while ongoing clinical studies continue in the outbreak zone.
“The treatment will now be made available for compassionate use in Congo while supporting ongoing clinical trials in the affected region,” U.S. health officials said.
Although the exact number of doses has not been disclosed, authorities noted that “the objective is to generate data that could support future regulatory review and potential approval of the treatment.”
The decision comes as health authorities struggle to contain an Ebola outbreak in eastern Congo that has recorded more than 1,000 infections and over 250 deaths.
The World Health Organization (WHO) warned that “the outbreak could become one of the most dangerous in recent years if response efforts are not significantly strengthened.”
The outbreak involves the Bundibugyo strain of Ebola, for which there are currently no approved vaccines or treatments. This has increased reliance on experimental therapies being tested under carefully monitored clinical trial conditions.
WHO confirmed that shipments of investigational treatments, including Mapp’s MBP134 antibody therapy and other promising candidates, are being delivered to support upcoming trials in the region.
The studies are being coordinated by partners in the Democratic Republic of Congo, Uganda, and international research institutions, including Oxford University.
MBP134 will be tested both as a standalone treatment and in combination with the antiviral drug remdesivir, developed by Gilead Sciences and widely used during the COVID-19 pandemic.
Another antiviral medication, obeldesivir, is also expected to be evaluated as a preventive option in separate studies led by African and international health organizations.
Health officials say vaccine development remains in its early stages, with initial Phase 1 trials potentially beginning as early as next month in the United Kingdom and possibly Uganda.
Leading candidates include vaccine programs developed by Oxford University in partnership with the Serum Institute of India, as well as mRNA vaccine candidates from Moderna.
However, experts caution that deploying vaccines in outbreak regions will take time due to manufacturing requirements, safety assessments, and regulatory approval processes.
Health agencies have also warned that conducting clinical trials in conflict-affected areas such as eastern Congo presents major challenges, including insecurity, community mistrust, and limited infrastructure.
Despite these obstacles, WHO maintains that clinical trials are essential.
“Clinical trials are critical for determining the safety and effectiveness of potential treatments and for improving responses to future outbreaks,” the agency said.
WHO further emphasized that “all experimental treatments must undergo rigorous evaluation before they can be approved for widespread use.”
The U.S. government has also pledged financial and technical support for Ebola response efforts across Africa, aiming to strengthen prevention measures and reduce the risk of cross-border transmission.
Health officials said the current outbreak highlights “the urgent need for coordinated international action as scientists race to develop effective treatments and vaccines against Ebola.”
